Rights and permissions
About this article
Cite this article
Is DOTS-plus worth it for TB in developing countries?. Pharmacoecon. Outcomes News 404, 9 (2003). https://doi.org/10.1007/BF03276004
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276004